Multi-modal bio-imaging technique based on 18F-FLT PET/CT imaging and dynamic contrast-enhanced nuclear magnetic resonance (DCE-MRI) for predicting the efficacy of radiotherapy for esophageal cancer

Status

Recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR1900022339

Enrollment

Unknown

Registered

2019-04-06

Start date

2019-04-15

Completion date

Unknown

Last updated

2021-07-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

esophageal squamous cell carcinoma

Interventions

A:Surgery only

B:Preoperative radiotherapy and chemotherapy

C:Radical chemoradiation

Eligibility

Sex/Gender

Male

Age

18 Years to 75 Years

Inclusion criteria

Inclusion criteria: Pathological diagnosis of esophageal cancer, no distant metastasis; pre-treatment examination: normal blood, liver transaminase and transpeptidase, serum creatinine, blood urea nitrogen less than 2 times normal; aged 18 to 75 years; signed informed consent.

Exclusion criteria

Exclusion criteria: Patients who have received previous chemoradiation. Reluctant to sign consent or non-cooperation due to patient or family reasons; due to psychological, social, family and geographical reasons, patients who are unable to cooperate with regular follow-up observers with severe uncontrollable infection or medical disease; major tube dysfunction, such as loss Compensatory heart, lung, kidney, liver failure, can not tolerate surgery.

Design outcomes

Primary

Measure	Time frame
tumor size;[18F]-FLT PET/CT;Ktrans;Kep;Ve;DWI;	—

Countries

China

Contacts

Public ContactWang Yi

Cancer Hospital of Sichuan Province

wangleo@126.com+86 18780048851

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026